Advances in SM

CE / CME

Advances in Systemic Mastocytosis: Getting to the Root of Disease With New and Emerging Targeted Treatments

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: December 16, 2024

Expiration: December 15, 2025

Matthew Giannetti
Matthew Giannetti, MD

Activity

Progress
1 2
Course Completed

Introduction 

In this module, Matthew Giannetti, MD, discusses the differential diagnosis and management of systemic mastocytosis (SM) and its subtypes as well as emerging treatment options for this complex disease.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with indolent systemic mastocytosis (ISM) do you provide care for in a typical week? 

A patient presents with symptoms suggestive of ISM. Which of the following would be considered the major criterion for diagnosis per the World Health Organization (WHO) 2022 guidelines? 

A patient presents for genetic testing for ISM. Which of the following genetic tests would be most appropriate for the patient to confirm the diagnosis?

I am familiar with key data for new and emerging targeted therapies for ISM and apply them to optimize care of patients.